Your browser version may not work well with NCBI's Web applications. More information here...
1: J Headache Pain. 2008 Feb;9(1):37-41. Epub 2008 Jan 23.Click here to read Links
Comment in:
J Headache Pain. 2008 Feb;9(1):3-4.

The effect of sodium valproate on chronic daily headache and its subgroups.

Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F.

Department of Neurology, School of Medicine, Suleyman Demirel University, 32260 Isparta, Turkey. vedatyurekli@yahoo.com

The objective of the study was to assess the efficacy and tolerability of sodium valproate (VPA) on chronic daily headache (CDH) in a prospective, double-blind, randomized, placebo-controlled trial. Seventy patients were included in the study. Twenty-nine had chronic migraine (CM) and 41 had chronic tension-type headache (CTTH). VPA and placebo were applied for 3 months to 40 and 30 patients, respectively. Visual analog scale (VAS) and pain frequency (PF) were used for evaluation. VPA decreased the maximum pain VAS levels (MaxVAS) and PF at the end of the study (P = 0.028 and P = 0.000, respectively), but did not change general pain VAS (GnVAS) levels (P = 0.198). In CM patients, the decreases in MaxVAS, GnVAS and PF parameters were more in VPA treated patients (P = 0.006, P = 0.03, and P = 0.000, respectively). VPA treatment caused more reduction in PF than placebo in the CTTH subgroup (P = 0.000). VPA is effective in the prophylactic treatment of CDH by reducing MaxVAS levels and PF. It was more effective in CM than in CTTH.

PMID: 18231713 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Valproic Acid (Depakene® , Depakote® , Depakote® ER, ...)

    Valproic acid is used alone or with other medications to treat certain types of seizures. Valproic acid is also used to treat mania (episodes of frenzied, abnormally excited mood) in people with bipolar disorder (manic-d...

  • Source: AHFS Consumer Medication Information